Exploring the principles behind antibiotics with limited resistance.

Area of Science:

• Microbiology
• Drug Discovery
• Molecular Biology

Background:

• Antibiotic resistance is a growing global health threat.
• Antibiotics targeting multiple cellular functions are predicted to reduce resistance.
• Dual-targeting strategies are crucial but may not be sufficient alone.

Purpose of the Study:

• To test the hypothesis that antibiotics simultaneously targeting membrane integrity and another cellular pathway exhibit reduced resistance.
• To evaluate the efficacy of three novel antibiotic candidates (POL7306, Tridecaptin M152-P3, SCH79797) against ESKAPE pathogens.
• To identify mechanisms that restrict resistance evolution to these dual-targeting antibiotics.

Main Methods:

• Testing antibiotic candidates against ESKAPE pathogens (Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa).
• Investigating resistance mechanisms including de novo mutations, gene amplification, and mobile resistance genes via functional metagenomics.
• Assessing bacterial population eradication upon exposure to membrane-targeting antibiotics.

Main Results:

• Limited resistance evolution observed against POL7306, Tridecaptin M152-P3, and SCH79797 in ESKAPE pathogens.
• Dual-targeting topoisomerase antibiotics showed higher susceptibility to resistance development.
• Mechanisms restricting resistance include limited impact of target mutations/efflux pumps, inaccessibility via gene amplification, and rarity of mobile resistance genes.
• Rapid bacterial eradication was observed with membrane-targeting antibiotics.

Conclusions:

• Antibiotics simultaneously targeting membrane integrity and another cellular pathway demonstrate reduced resistance development.
• Common resistance mechanisms in pathogens offer limited protection against these novel antibiotics.
• These findings provide critical guidelines for developing next-generation antibiotics to combat resistance.